Iovance Biotherapeutics' (IOVA) CEO Fred Vogt on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 11/05/21
Iovance Biotherapeutics Reports Third Quarter and Year-to-Date 2021 Financial Results and Corporate UpdatesGlobeNewsWire • 11/04/21
Iovance Biotherapeutics (IOVA) Sees Hammer Chart Pattern: Time to Buy?Zacks Investment Research • 11/03/21
Wall Street Analysts Think Iovance Biotherapeutics (IOVA) Could Surge 52%: Read This Before Placing a BetZacks Investment Research • 10/27/21
Iovance Biotherapeutics to Host Third Quarter Financial Results Conference Call and Webcast on Thursday, November 4, 2021GlobeNewsWire • 10/25/21
Iovance Biotherapeutics to Host Conference Call and Webcast to Highlight Data at Society for Immunotherapy of Cancer (SITC) Annual MeetingGlobeNewsWire • 10/18/21
Does Iovance Biotherapeutics (IOVA) Have the Potential to Rally 49% as Wall Street Analysts Expect?Zacks Investment Research • 10/11/21
Iovance Biotherapeutics to Present Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Cell Therapies Across Multiple Solid Tumors and Treatment Settings at the Society for Immunotherapy of Cancer's (SITC) 36th Annual MeetingGlobeNewsWire • 10/01/21
Iovance Biotherapeutics Celebrates Grand Opening of Iovance Cell Therapy Center (iCTC) in the Philadelphia Navy YardGlobeNewsWire • 09/28/21
Iovance Biotherapeutics Initiates Clinical Supply of Tumor-Infiltrating Lymphocyte (TIL) Cell Therapy Manufactured at Iovance Cell Therapy Center (iCTC)GlobeNewsWire • 09/23/21
Iovance Biotherapeutics, Inc. (IOVA) CEO Frederick Vogt on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 08/06/21
Iovance Biotherapeutics Reports Second Quarter and First Half 2021 Financial Results and Corporate UpdatesGlobeNewsWire • 08/05/21
Iovance Biotherapeutics to Host Second Quarter Financial Results Conference Call and Webcast on Thursday, August 5, 2021GlobeNewsWire • 07/19/21
Iovance Biotherapeutics to Host Conference Call and Webcast to Discuss Clinical Data for LN-145 in Non-Small Cell Lung Cancer on June 29, 2021 at 4:30pm ETGlobeNewsWire • 06/29/21
Iovance Biotherapeutics' TIL Therapy Achieves ORR Of 21.4% In Pre-Treated Lung Cancer PatientsBenzinga • 06/29/21
Iovance Biotherapeutics Announces Clinical Data for LN-145 in Non-Small Cell Lung CancerGlobeNewsWire • 06/29/21